Main Focuses

Against the background of a dynamic development in oncology, new therapeutic approaches and individualized medical strategies, diagnostics and therapy decisions are increasingly interdependent.

All pillars of oncological in vitro diagnostics are represented in the IIG:

  • Biochemistry of tumor-specific metabolites
  • Bone marrow cytology
  • Immunophenotyping
  • Tumor cytogenetics
  • Molecular tumor genetics / Molecular pathology
  • Genetic analysis of predisposing factors including hereditary tumor syndromes

The broad diagnostic concept enables an interactive procedure as well as valuable plausibility checks and ensures short processing times.

One instrument of individualized medicine in oncology is the analysis of complex genetic mutation patterns (multigene analysis, comparative whole exome sequencing) in solid tumors in combination with evidence-based data analysis.

In a group of clinical oncologists, pathologists, geneticists and laboratory physicians, the most promising therapy strategy is developed together with the treating oncologist. This includes the avoidance of severe side effects for the benefit of quality of life during therapy as well as the choice of the most efficient active substances and, if necessary, the argumentative rationale towards cost bearers (guidelines, study situation, current publications).

The Corporate Oncology Program for Employees (COPE) is aimed at employees of participating companies who have developed malignant solid tumors. It gives you the opportunity to have an innovative personalized tumor analysis prepared.

Prof. Dr. med. Wolfram Henn (Tumor cytogenetics, Molecular tumor genetics)
Phone: +49 (0)631 / 316 70-0

Dipl.-Biol. Annette Wodsack (Tumor cytogenetics)
Phone: +49 (0)631 / 316 70-0

Dipl.-Biol. Thomas Alef (Molecular tumor genetics)
Phone: +49 (0)631 / 316 70-0

Dr. rer. nat. Konstantinos Romanakis (Immunophenotyping)
Phone: +49 (0)631 / 316 70-0